MX2014013566A - Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. - Google Patents

Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases.

Info

Publication number
MX2014013566A
MX2014013566A MX2014013566A MX2014013566A MX2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A
Authority
MX
Mexico
Prior art keywords
hyperammonemia
acute
hepatic encephalopathy
vitro
gene therapy
Prior art date
Application number
MX2014013566A
Other languages
Spanish (es)
Inventor
Miguel A Torres Vega
Original Assignee
Inst Nac De Ciencias Medicas Y Nutricion Salvador Zubiran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nac De Ciencias Medicas Y Nutricion Salvador Zubiran filed Critical Inst Nac De Ciencias Medicas Y Nutricion Salvador Zubiran
Priority to MX2014013566A priority Critical patent/MX2014013566A/en
Publication of MX2014013566A publication Critical patent/MX2014013566A/en

Links

Abstract

The present disclosure is related to the production of a new drug for the treatment of Hepatic Encephalopathy (HE), which consists of recombinant viruses, in particular baculoviruses, which over-expresses one or more of the ammonia metabolism enzymes including Glutamine synthetase (GS), in various tissues of the patient and with the purpose of reducing the acute hyperammonemia and relief the signs and symptoms of HE. The recombinant baculovirus Bac-GS developed in the present invention expresses the RNAm and the GS and, as a result, reduces the levels of ammonium in the in-vitro and in-vivo medium. For this purpose, a new in-vitro hyperammonemia model was generated. This new drug called Bac-GS can be used to reduce acute hyperammonemia in patients with urea cycle disorders and other diseases with high ammonia levels, such as: acute and chronic liver failure, hepatocellular carcinoma and diseases related to neuropsychiatric disorders.
MX2014013566A 2014-11-07 2014-11-07 Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. MX2014013566A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2014013566A MX2014013566A (en) 2014-11-07 2014-11-07 Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2014013566A MX2014013566A (en) 2014-11-07 2014-11-07 Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases.

Publications (1)

Publication Number Publication Date
MX2014013566A true MX2014013566A (en) 2016-05-09

Family

ID=56797787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013566A MX2014013566A (en) 2014-11-07 2014-11-07 Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases.

Country Status (1)

Country Link
MX (1) MX2014013566A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065082A1 (en) * 2018-09-28 2020-04-02 Thoeris Gmbh Use of glutamine synthetase for treating fatty liver disease
US11932885B2 (en) 2017-05-24 2024-03-19 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932885B2 (en) 2017-05-24 2024-03-19 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
WO2020065082A1 (en) * 2018-09-28 2020-04-02 Thoeris Gmbh Use of glutamine synthetase for treating fatty liver disease

Similar Documents

Publication Publication Date Title
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12018502593A1 (en) Combinations of linagliptin and metformin
PH12020500555A1 (en) Esketamine for the treatment of depression
PH12015500431B1 (en) Glucosylceramide synthase inhibitors
BR112015007616A2 (en) mek inhibitors in the treatment of virus diseases
MX2019005435A (en) Pharmaceutical composition, methods for treating and uses thereof.
PH12018501443A1 (en) Methods of administering hepcidin
MX2016000220A (en) Regulation of glucose metabolism using anti-cgrp antibodies.
TN2015000427A1 (en) Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
EA201790563A8 (en) APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY
EA201991175A1 (en) THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS
BR112018067554A2 (en) testosterone formulations and treatment methods with them
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2014013566A (en) Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases.
MX2018005312A (en) Compositions and methods for treatment of homocystinuria.
PH12019501358A1 (en) Methods of administering hepcidin
UA111116C2 (en) Balanced infusion solution
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
MD596Y (en) Method for treating the chronic viral hepatitis C
Micheli Piribedil/pramipexole/ropinirole
EA201990676A1 (en) OSTEOARTHRITIS TREATMENT
EA201892048A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGAGLIFLOZIN, AND ITS APPLICATIONS
Hahn Diarrhoea: case report
UA114982U (en) METHOD OF TREATMENT OF PATIENTS WITH CHRONIC PURPLE EXTREMELY SYNUIT WITH TYPE 1 DIABETES